# LIST OF CONTENTS

<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>i</td>
</tr>
<tr>
<td>Dedication</td>
<td>iv</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>v</td>
</tr>
<tr>
<td>Undertaking (Declaration) by the Scholar</td>
<td>vi</td>
</tr>
<tr>
<td>Supervisor’s Certificate</td>
<td>viii</td>
</tr>
<tr>
<td>Co-supervisor’s Certificate</td>
<td>ix</td>
</tr>
<tr>
<td>Contents with Page Number</td>
<td>x</td>
</tr>
<tr>
<td>List of Tables</td>
<td>xiii</td>
</tr>
<tr>
<td>List of Figures</td>
<td>xiv</td>
</tr>
<tr>
<td>Abbreviation &amp; Acronyms</td>
<td>xvi</td>
</tr>
<tr>
<td>List of Appendices</td>
<td>xvii</td>
</tr>
<tr>
<td>Chapter Scheme</td>
<td>xviii</td>
</tr>
</tbody>
</table>

## 1 Introduction

1.1 Metabolic Syndrome  
2.1 Definition and diagnostic criteria of metabolic syndrome  
2.1.1 World health organization (WHO) criteria-1998  
2.1.2 The European Group for the study of Insulin Resistance (EGIR) criteria-1999  
2.1.3 National Cholesterol Education Program Adult Treatment Panel-III (NCEP: ATP-III) criteria-2003  
2.1.4 American Association of clinical endocrinology criteria-2003  
2.1.5 International Diabetes Federation (IDF) criteria-2005  
2.1.6 American Heart Association / National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria-2004  
2.1.7 Consensus definition (Incorporating IDF and AHA/NHLBI definitions)  
2.3 Components of MS as modified NCEP: ATP-III criteria  

x
2.3.1 Hyperglycemia 9
2.3.2 Body Mass Index (BMI) 10
2.3.3 Central Obesity 11
2.3.4 Hypertriglyceridemia 12
2.3.5 High-Density Lipoprotein cholesterol 13
2.3.6 Blood Pressure 13

2.4 Prevalence of Metabolic Syndrome 15
2.4.1 Global prevalence of metabolic syndrome 15
2.4.2 Prevalence of metabolic syndrome in Asia 15
2.4.3 Prevalence of metabolic syndrome in India 17
   2.4.3.1 Prevalence of metabolic syndrome in Urban population of India 17
   2.4.3.2 Prevalence of metabolic syndrome in rural population of India 20

2.5 Complications of metabolic syndrome 21
2.6 Organs affected in metabolic syndrome 21
2.7 Renal dysfunction in metabolic syndrome 22
2.8 Other manifestations 28
   2.8.1 Pro-inflammatory state 28
   2.8.2 Pro-thrombotic state 29
   2.8.3 Life style modification and drug therapy in prevention and management of metabolic syndrome and its renal complication 29

2.9 Five stages of kidney diseases 29

3. Material and Methods 32-47
   3.1 Inclusion criteria 32
   3.2 Exclusion criteria 32
   3.3 Sample size 32
   3.4 Ethics committee approval 33
   3.5 Biochemical evaluation 33
      3.5.1 Blood collection 33
      3.5.2 Urine collection 33
      3.5.3 Plasma fasting glucose 34
      3.5.4 Serum urea 36
3.5.5 Serum creatinine 38
3.5.6 Serum triglycerides 40
3.5.7 Serum HDLc 42
3.5.8 Urine protein detection 44
3.5.9 Creatinine clearance 45
3.5.10 Estimated glomerular filtration rate (eGFR) 46

3.6 Anthropometric measurements 47
3.6.1 Waist circumference 47
3.6.2 Height 47
3.6.3 Weight 47
3.6.4 Body mass index (BMI) 47
3.6.5 Hypertension 47
3.6.6 Socio-demographic classification 47

3.7 Statistics 47

4. Results 48-89
4.1 Age and sex distribution 48
4.1a Relationship with life style & Socio-demographic Status 51
4.2 Prevalence of MS criteria 52
4.2.1 BMI 60
4.2.2 HDLc 63
4.2.3 FPG 66
4.2.4 TG 70
4.2.5 BP 71
4.3 Renal function tests (RFTs) 72
4.4 Correlations 79

5. Discussion 90-96
5.1 Prevalence of MS 90
5.2 Age and sex ratio 90
5.3 Life style and socio-demographic classes 91
5.4 BMI 91
5.5 MS criteria 92
5.6 CKD and eGFR 93

6. Summary and Conclusion 97-98

8. Bibliography 99-124